News
PRCT
35.86
+1.21%
0.43
PROCEPT BioRobotics Price Target Cut to $51.00/Share From $56.00 by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $51
Benzinga · 3d ago
Procept BioRobotics price target lowered to $51 from $56 at Morgan Stanley
TipRanks · 4d ago
Weekly Report: what happened at PRCT last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at PRCT last week (1117-1121)?
Weekly Report · 11/24 10:01
First Week of July 2026 Options Trading For PROCEPT BioRobotics (PRCT)
NASDAQ · 11/21 16:10
PROCEPT BioRobotics To Spotlight Aquablation Growth At Piper Sandler Event Next Month
NASDAQ · 11/21 11:19
Artisan Global Discovery Fund: Q3 Delivers Strong Results Amid Trimming And Exits
Seeking Alpha · 11/20 13:40
Weekly Report: what happened at PRCT last week (1110-1114)?
Weekly Report · 11/17 10:01
Procept Biorobotics Showcases Aquablation Therapy as Next-Generation BPH Solution in Investor Presentation
Reuters · 11/10 22:23
Piper Sandler Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
TipRanks · 11/10 12:19
Weekly Report: what happened at PRCT last week (1103-1107)?
Weekly Report · 11/10 09:59
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
Dow Jones · 11/05 18:49
PROCEPT BioRobotics Price Target Cut to $50.00/Share From $85.00 by TD Cowen
Dow Jones · 11/05 18:49
TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $50
Benzinga · 11/05 18:39
Analysts’ Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Day One Biopharmaceuticals (DAWN) and Exelixis (EXEL)
TipRanks · 11/05 16:30
PROCEPT BioRobotics Price Target Cut to $50.00/Share From $55.00 by Piper Sandler
Dow Jones · 11/05 16:01
Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Lowers Price Target to $50
Benzinga · 11/05 15:51
PROCEPT BioRobotics Is Maintained at Overweight by Wells Fargo
Dow Jones · 11/05 15:36
PROCEPT BioRobotics Price Target Cut to $51.00/Share From $58.00 by Wells Fargo
Dow Jones · 11/05 15:36
More
Webull provides a variety of real-time PRCT stock news. You can receive the latest news about Procept Biorobotics Corp through multiple platforms. This information may help you make smarter investment decisions.
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.